NVIDIA's BioNeMo Platform Reaches Eli Lilly and Thermo Fisher in Global Pharma AI Push
NVIDIA's BioNeMo AI platform has been adopted by pharmaceutical giants Eli Lilly and Thermo Fisher Scientific for drug discovery automation. The expansion positions NVIDIA as infrastructure provider to a global pharmaceutical industry seeking to compress decade-long development timelines. The move reflects worldwide competition between licensing external AI platforms and building proprietary capabilities.
Salvado•